Genmab A/S
GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivaā¦ read more
Healthcare
Biotechnology
17 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$32.23
Price-2.45%
-$0.81
1Y
Price
Market Cap
$19.787b
Large
Price/Earnings 3y Avg5y Avg
24.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+37.3%
EBITDA Margin+26.2%
Net Profit Margin+4.2%
Free Cash Flow Margin+37.3%
EBITDA Margin+26.2%
Net Profit Margin+4.2%
Free Cash Flow MarginRevenue
$4.131b
+11.0%
1y CAGR-13.7%
3y CAGR-6.9%
5y CAGREarnings
$788.103m
-18.2%
1y CAGR-8.6%
3y CAGR-11.5%
5y CAGREPS
$1.27
-17.5%
1y CAGR-7.0%
3y CAGR-10.2%
5y CAGRBook Value
$5.957b
$12.515b
Assets$6.558b
Liabilities$5.273b
DebtDebt to Assets
42.1%
4.3x
Debt to EBITDAFree Cash Flow
$867.344m
-24.6%
1y CAGR-33.7%
3y CAGR-1.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company